Comparative Effectiveness of Enteral Nutrition and Immunomodulators in Inducing and Maintaining Remission in Pediatric Crohn's Disease: A Systematic Review and Network Meta-Analysis - Report - MDSpire
Advertisement
Comparative Effectiveness of Enteral Nutrition and Immunomodulators in Inducing and Maintaining Remission in Pediatric Crohn's Disease: A Systematic Review and Network Meta-Analysis
Clinical Report: Comparative Effectiveness of Enteral Nutrition in Pediatric Crohn's Disease
Overview
This systematic review and network meta-analysis evaluates the efficacy and safety of enteral nutrition (EN) therapies compared to immunomodulators and corticosteroids in pediatric Crohn's disease. Findings indicate that exclusive enteral nutrition (EEN) and the Crohn's Disease Exclusion Diet plus partial enteral nutrition (CDED + PEN) are superior for inducing clinical and mucosal remission, with better safety profiles.
Background
Pediatric Crohn's disease (CD) presents unique challenges, including growth impairment and psychosocial concerns, necessitating effective treatment strategies. Traditional therapies like corticosteroids have significant adverse effects, prompting the exploration of enteral nutrition as a viable alternative. Understanding the comparative effectiveness of these therapies is crucial for optimizing treatment and improving patient outcomes.
Data Highlights
Intervention
Outcome
Odds Ratio (OR)
95% Confidence Interval (CI)
EEN vs. CS
Clinical remission induction
1.72
1.18–2.52
EEN vs. CS
Mucosal healing
7.55
3.59–15.88
AZA/6-MP vs. Placebo
Maintenance
12.50
2.47–63.14
Key Findings
EEN is significantly superior to corticosteroids for clinical remission induction (OR 1.72).
EEN demonstrates marked superiority for mucosal healing compared to corticosteroids (OR 7.55).
SUCRA rankings for remission induction place CDED + PEN and EEN at the top.
AZA/6-MP is superior to placebo for maintenance therapy (OR 12.50).
EN therapies have a favorable safety profile with serious adverse events ranging from 0% to 3.1%.
Immunomodulators remain essential for maintenance therapy despite the effectiveness of EN for induction.
Clinical Implications
The findings support the use of enteral nutrition as a first-line induction therapy in pediatric Crohn's disease, particularly for patients with mild to moderate disease. Clinicians should consider the favorable safety profiles of EN therapies when developing treatment plans, especially in pediatric populations.
Conclusion
EEN and CDED + PEN are effective and safe options for inducing remission in pediatric Crohn's disease, while immunomodulators play a critical role in maintenance therapy. These insights can guide clinical decision-making and treatment strategies.
